<DOC>
	<DOCNO>NCT00211705</DOCNO>
	<brief_summary>To evaluate primary preventive effect low-dose pravastatin coronary heart disease ( CHD ) Japanese hypercholesterolemic patient .</brief_summary>
	<brief_title>Management Elevated Cholesterol Primary Prevention Group Adult Japanese ( MEGA Study )</brief_title>
	<detailed_description>MEGA Study first prospective , randomize , control trial conduct Japan evaluate primary preventive effect pravastatin CHD daily clinical practice . Because dose pravastatin use MEGA Study 10–20 mg/day , consistent approve dos Japan low dos use previous large-scale clinical trial .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>TC:220～270mg/dl Male : 4070 year old/ female : postmenopausal70 year old &lt; 40kg weight FH History CHD ( angina , MI , postPTCA/CABG , etc . ) History CVA ( stroke , TIA , etc . ) Underlying malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>prevention</keyword>
	<keyword>stroke</keyword>
	<keyword>pravastatin</keyword>
</DOC>